BMS, Celgene tout synergies in $74B mega-deal, but Revlimid’s winter is coming
Source: http://bit.ly/2VtWi3H
In a call to following news of the deal, executives pointed to near-term launch opportunities and pipelines, but some analysts expressed concern about the loss of patent protection for Revlimid and Opdivo.
Source: http://bit.ly/2VtWi3H
0 Comments